[Federal Register Volume 79, Number 237 (Wednesday, December 10, 2014)]
[Notices]
[Pages 73279-73280]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2014-28951]
-----------------------------------------------------------------------
DEPARTMENT OF COMMERCE
Patent and Trademark Office
[Docket No. PTO-P-2014-0067]
Grant of Interim Extension of the Term of U.S. Patent No.
5,496,801; Recombinant Human Parathyroid Hormone
AGENCY: United States Patent and Trademark Office, Commerce.
ACTION: Notice of interim patent term extension.
-----------------------------------------------------------------------
SUMMARY: The United States Patent and Trademark Office has issued an
order granting interim extension under 35 U.S.C. 156(d)(5) for a second
one-year interim extension of the term of U.S. Patent No. 5,496,801.
FOR FURTHER INFORMATION CONTACT: Mary C. Till by telephone at (571)
272-7755; by mail marked to her attention and addressed to the
Commissioner for Patents, Mail Stop Hatch-Waxman PTE, P.O. Box 1450,
Alexandria, VA 22313-1450; by fax marked to her attention at (571) 273-
7755; or by email to [email protected].
SUPPLEMENTARY INFORMATION: Section 156 of Title 35, United States Code,
generally provides that the term of a patent may be extended for a
period of up to five years if the patent claims a product, or a method
of making or using a product, that has been subject to certain defined
regulatory review, and that the patent may be extended for interim
periods of up to one year if the regulatory review is anticipated to
extend beyond the expiration date of the patent.
On October 29, 2014, NPS Pharmaceuticals, Inc., timely filed an
application under 35 U.S.C. 156(d)(5) for a second interim extension of
the term of U.S. Patent No. 5,496,801. The patent claims the human
biological product recombinant human parathyroid hormone. The
application indicates that Biologics License Application 125511 for the
drug product, recombinant human parathyroid hormone, was filed on
October 24, 2013, and is currently undergoing regulatory review before
the Food and Drug Administration for permission to market or use the
product commercially.
Review of the application indicates that, except for permission to
market or use the product commercially, the subject patent would be
eligible for an extension of the patent term under 35 U.S.C. 156, and
that the patent should be extended for one year as required by 35
U.S.C. 156(d)(5)(B). Because the regulatory review period will continue
beyond the extended expiration date of the patent, December 23, 2014,
interim extension of the patent term under 35 U.S.C. 156(d)(5) is
appropriate.
An interim extension under 35 U.S.C. 156(d)(5) of the term of U.S.
Patent No. 5,496,801 is granted for a period of one year from the
extended expiration date of the patent.
[[Page 73280]]
Dated: December 5, 2014.
Andrew Hirshfeld,
Deputy Commissioner for Patent Examination Policy, United States Patent
and Trademark Office.
[FR Doc. 2014-28951 Filed 12-9-14; 8:45 am]
BILLING CODE 3510-16-P